Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase

AbstractTo explore the differences in glucose-lipid metabolism profiles among the 3 TKIs, we designed a retrospective study to compare the onset of hyperglycaemia, hypertriglyceridemia, hypercholesterolemia and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients with normal baseline glucose-lipid profiles and had no medical record of cardio- or cerebro-vascular diseases and/or metabolic syndrome diseases, and identify variables associated with them. 370 chronic myeloid leukaemia patients receiving dasatinib, nilotinib or imatinib therapy ≥3 months were retrospectively reviewed. During TKI-therapy, the mean fasting glucose, triglyceride, cholesterol, and LDL-cholesterol levels increased significantly in both dasatinib and nilotinib cohorts compared with the imatinib cohort. In multivariate analyses, dasatinib was the factor significantly associated with both poor hyperglycaemia- and hypertriglyceridemia-free survival. In addition, nilotinib was significantly associated with more occurrences of hyperglycaemia and hypercholesterolemia; increasing age was significantly associated with more occurrences of hyperglycaemia and hypertriglyceridemia. We concluded that dasatinib, similar to nilotinib, has the adverse impact on glucose-lipid metabolism compared with imatinib.

Download Full-text

On the Severity of Carpal Tunnel Syndrome: Metabolic Syndrome or Obesity

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2020.5273 ◽

2020 ◽

Vol 8 (A) ◽

pp. 606-610

Author(s):

Angelo Vasiliadis ◽

George Charitoudis ◽

Theofanis Kantas ◽

George Giovanidis ◽

George Biniaris

Keyword(s):

Metabolic Syndrome ◽

Waist Circumference ◽

Low Density Lipoprotein ◽

Fasting Blood Glucose ◽

Density Lipoprotein ◽

Low Density Lipoprotein Cholesterol ◽

Cholesterol Levels ◽

Tunnel Syndrome ◽

The Mean ◽

The Relationship

AIM: This study aimed to determine the relationship between CTS, metabolic syndrome and obesity and to compare the severity of CTS between patients with or without metabolic syndrome (MS) and patients with or without obesity. METHODS: In this prospective study, patients with clinical and electrophysiological confirmed diagnosis of CTS were included. The waist circumference, blood pressure, fasting blood glucose, fasting triglycerides and high/low density lipoprotein cholesterol levels were recorded. Patients were categorized having metabolic syndrome according to Adult Treatment Panel III definition, while body mass index was used to identify obesity. RESULTS: A total of 65 patients with a mean age of 58.91 ± 12.49 years were included. MS was found in 39 (60%) patients and obesity in 27 (41.5%) patients. The CTS was described as mild, moderate and severe in 8, 12 and 19 hands of those with MS and in 2, 6, and 18 of those without MS respectively (p = 0.207). There were no statistically significant results observed between BMI and the severity of CTS (p > 0.05). The mean waist circumference was 94.75 ± 7.36, 98.78 ± 9.64, 106.42 ± 10.78, 86.41 ± 6.77 for patients with MS+_O–, MS–O+_, MS+_O+_ _and MS–O– _respectively (p < 0.002). CONCLUSION: CTS appears to be more severe in patients with MS than in patients with obesity. Central obesity is one of the well-known risk factors for CTS, but components of MS may have a greater effect on the severity of CTS.

Download Full-text

High Triglyceride/HDL Cholesterol Ratio is Associated with Silent Brain Infarcts in a Healthy Population

10.21203/rs.2.9432/v2 ◽

2019 ◽

Author(s):

Ki-Woong Nam(Former Corresponding Author) ◽

Hyung-Min Kwon(New Corresponding Author) ◽

Han-Yeong Jeong ◽

Jin-Ho Park ◽

Hyuktae Kwon ◽

...

Keyword(s):

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Vascular Diseases ◽

Hdl Cholesterol ◽

Cerebrovascular Diseases ◽

Healthy Population ◽

Cholesterol Ratio ◽

Silent Brain Infarct ◽

Cholesterol Levels

Abstract Background: Triglycerides (TG)/high-density lipoprotein (HDL) cholesterol ratio is a marker of small/dense low-density lipoprotein particles, which are closely associated with various metabolic and vascular diseases. However, the role of TG/HDL cholesterol ratio in cerebrovascular diseases has not been well studied. In this study, we evaluated the relationship between TG/HDL cholesterol ratio and the presence of silent brain infarct (SBI) in a neurologically healthy population. Methods: We retrospectively evaluated consecutive participants in health check-ups between January 2006 and December 2013. SBI was defined as an asymptomatic, well-defined lesion with a diameter of ≥ 3 mm on T1- or T2-weighted images. TG/HDL cholesterol ratio was calculated after dividing absolute TG levels by absolute HDL cholesterol levels. Results: Of 3,172 healthy participants, 263 (8.3%) had SBI lesions. In multivariate analysis, TG/HDL cholesterol ratio was independently associated with SBI (adjusted odds ratio [aOR] = 1.16, 95% confidence interval [CI] = 1.00 to 1.34, P = 0.047). This association was prominent in males (aOR = 1.23, 95% CI = 1.03 to 1.48, P = 0.021), but not in females. In the analyses of the relationships between lipid parameters and SBI lesion burden, TG/HDL cholesterol ratio was positively correlated, and total cholesterol/TG ratio was negatively correlated with SBI lesion burden, in dose-response manners (P for trend = 0.015 and 0.002, respectively). Conclusions: The TG/HDL cholesterol ratio was positively associated with the prevalence of SBI in a neurologically healthy population.

Download Full-text

High Triglyceride/HDL Cholesterol Ratio is Associated with Silent Brain Infarcts in a Healthy Population

10.21203/rs.2.9432/v3 ◽

2019 ◽

Author(s):

Ki-Woong Nam ◽

Hyung-Min Kwon(Former Corresponding Author) ◽

Han-Yeong Jeong ◽

Jin-Ho Park(New Corresponding Author) ◽

Hyuktae Kwon ◽

...

Keyword(s):

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Vascular Diseases ◽

Hdl Cholesterol ◽

Cerebrovascular Diseases ◽

Healthy Population ◽

Cholesterol Ratio ◽

Silent Brain Infarct ◽

Cholesterol Levels

Download Full-text

A maple syrup extract alters lipid metabolism in obese type 2 diabetic model mice

Nutrition & Metabolism ◽

10.1186/s12986-019-0403-2 ◽

2019 ◽

Vol 16 (1) ◽

Author(s):

Tsudoi Toyoda ◽

Asuka Kamei ◽

Tomoko Ishijima ◽

Keiko Abe ◽

Shinji Okada

Keyword(s):

Lipid Metabolism ◽

Bile Acid ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Diabetic Mouse ◽

Total Bile Acid ◽

Maple Syrup ◽

Bile Acid Level ◽

Cholesterol Levels ◽

Expression Of Genes

Abstract Background Some polyphenols are known to improve the symptoms of diabetes. In the present study, we investigated the effects of a polyphenol-rich extract of maple syrup (MSx) on a diabetic mouse model. Methods KK-Ay mice were fed a normal or 0.05% MSx-supplemented diet for 42 days. Body weight, food intake, serum biochemical parameters, and fecal total bile acid were measured. Gene expression of liver and epididymal white adipose tissue (WAT) and cecal microbiota were analyzed. Data were analyzed with an unpaired two-tailed Student’s t test or Welch’s t test according to the results of the F test. Results Serum low-density lipoprotein cholesterol levels were significantly reduced in mice that consumed MSx. Hepatic genes related to fatty acid degradation and cholesterol catabolism were upregulated in mice that consumed MSx. In contrast, the expression of genes related to lipid metabolism in WAT was unaffected by the intake of MSx. There were no significant differences between the two groups in terms of total bile acid level in the feces and the relative abundance of bacteria in the cecum. Conclusion Our results primarily indicate that MSx can help alleviate one of the symptoms of dyslipidemia.

Download Full-text

Efficacy of statin therapy in primary care — OZIRKA trial: population study on the effectiveness of Ozalex (rosuvastatin) in the treatment of patients with lipid metabolism disorders and hypercholesterolemia in different categories of patients

HYPERTENSION ◽

10.22141/2224-1485.13.6.2020.223076 ◽

2020 ◽

Vol 13 (6) ◽

pp. 5-14

Author(s):

Yu.M. Sirenko ◽

O.O. Torbas ◽

S.M. Kushnir

Keyword(s):

Primary Care ◽

Lipid Metabolism ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Low Density Lipoprotein Cholesterol ◽

Cholesterol Levels ◽

Lipid Metabolism Disorders

Background. In Ukraine, the number of statin prescriptions in recent years remains relatively low. A large-scale Ukrainian study OZIRKA would disprove some of the myths and demonstrate that long-term therapy with one of the most effective statins — rosuvastatin — in moderate and high doses is safe and effective in a large cohort of patients during primary care. The purpose of the study was to demonstrate the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia. Materials and methods. The study was planned as a prospective, open-label, population one. Recruitment of patients was done from March to December 2019. The analysis of the study data was conducted from June to November 2020. All patients had to receive rosuvastatin (Ozalex, Kusum Pharm, Ukraine) at a dose of 10 or 20 mg. Results. A total of 20,000 patients from all over Ukraine were planned to be included in the study. The full follow-up period was completed by 18,100 patients, of whom 17,530 had all the necessary data, so they were included in the final analysis. The mean follow-up period was 2.2 months. During the two months of follow-up, patients on average showed a significant reduction in total cholesterol levels — by 28 % (p < 0.001), low-density lipoprotein cholesterol — by 34 % (p < 0.001), triglycerides — by 25 % (p < 0.001). Increasing the dose of rosuvastatin from 10 to 20 mg after the first visit resulted in an additional reduction in low-density lipoprotein cholesterol by approximately 40 %. The fasting blood glucose level in the patients in this study reduced significantly, from 5.70 ± 0.01 mmol/l to 5.23 ± 0.01 mmol/l (significance of the dynamics of p < 0.001). Conclusions. Ozalex, manufactured by Kusum Pharm (Ukraine), is a highly effective generic drug of rosuvastatin, which has a neutral effect on glucose metabolism and allows achieving good control of blood lipids at the stage of primary care.

Download Full-text

A multicenter prospective hospital-based cohort study on the efficacy and safety of pitavastatin.

Current Diabetes Reviews ◽

10.2174/1573399817666201228164243 ◽

2020 ◽

Vol 17 ◽

Author(s):

Abdullah Shehab ◽

Asim Ahmed Elnour ◽

Akshaya Srikanth Bhagavathula ◽

Joseph Pulavelil Kurian ◽

Gazi Hassan ◽

...

Keyword(s):

Cohort Study ◽

Adverse Events ◽

United Arab Emirates ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Efficacy And Safety ◽

Onset Diabetes ◽

The Mean ◽

New Onset

Aims: We aim to investigate the efficacy and safety of pitavastatin 4 mg in a population of people living in the United Arab Emirates (UAE). Background: Pitavastatin is a member of the HMG-CoA reductase inhibitors family which was approved for use in adult subjects with primary hyperlipidemia or mixed dyslipidemia. To date, no published studies have assessed the efficacy and safety of pitavastatin in the United Arab Emirates. Objective: The main objective of the current study was to investigate the efficacy and safety of pitavastatin in subjects with dyslipidemia for primary prevention of cardiovascular diseases based on total cardiovascular risk. Methods: This was a multicentre (four private hospitals) prospective cohort study to analyze data on the use of pitavastatin for dyslipidemia in adult outpatients in Abu Dhabi and Dubai emirates, United Arab Emirates. We have followed-up the clinical profiles of subjects in four hospitals for six-weeks during the period from June 2015 to June 2017. Efficacy was based on the evaluation of the mean (± standard deviation) change in low-density lipoprotein cholesterol between baseline and week six after the initiation of pitavastatin therapy. Safety was reported as the incidence of adverse events occurred with the use of pitavastatin and the development of new-onset diabetes. Results: A total of 400 subjects who were receiving pitavastatin 4 mg were included. The mean age of subjects was 50.7 ±10.8 years, of these 79.0% were males. At the baseline, the mean level of total cholesterol was 185.4 ±41.5 mg/dL, low density lipoprotein was 154.9 ±48.55 mg/dL, high-density lipoprotein cholesterol was 40.5 ±11.23 mg/dL and fasting blood glucose was 115.0 (±16.63) mg/dl. At the end of six weeks, low density lipoprotein levels significantly decreased to 112.09 ±41.90 mg/dl (standard mean difference [SMD] (-42.8%), 95% CI: -42.88 [-49.17 to -36.58] mg/dl, P <0.001), while high density lipoprotein levels improved (SMD, 95% CI: 1.77% [0.25 to 3.28] mg/dl, P <0.022). There were 55 subjects (13.7%) reported various adverse events such as myalgia (7.5%), sleep disorders (2.5%), and myopathy (2.2%). Furthermore, 4 (1.0%) have had developed new-onset diabetes post six-weeks of initiation of pitavastatin therapy. Conclusion: Pitavastatin 4 mg had howed robust efficacy in reducing LDL-C levels and improving HDL-C levels in subjects with dyslipidemias. The use of pitavastatin was associated with a low discontinuation rate, fewer adverse events, and very limited cases of new-onset diabetes.

Download Full-text

Differences in the Effects of Anthocyanin Supplementation on Glucose and Lipid Metabolism According to the Structure of the Main Anthocyanin: A Meta-Analysis of Randomized Controlled Trials

Nutrients ◽

10.3390/nu13062003 ◽

2021 ◽

Vol 13 (6) ◽

pp. 2003

Author(s):

Risa Araki ◽

Akira Yada ◽

Hirotsugu Ueda ◽

Kenichi Tominaga ◽

Hiroko Isoda

Keyword(s):

Lipid Metabolism ◽

Meta Analysis ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Resistance Index ◽

Lipoprotein Cholesterol ◽

Controlled Trials ◽

Oh Groups ◽

Chemical Structures ◽

Glucose And Lipid Metabolism

The effectiveness of anthocyanins may differ according to their chemical structures; however, randomized clinical controlled trials (RCTs) or meta-analyses that examine the consequences of these structural differences have not been reported yet. In this meta-analysis, anthocyanins in test foods of 18 selected RCTs were categorized into three types: cyanidin-, delphinidin-, and malvidin-based. Delphinidin-based anthocyanins demonstrated significant effects on triglycerides (mean difference (MD): −0.24, p < 0.01), low-density lipoprotein cholesterol (LDL-C) (MD: −0.28, p < 0.001), and high-density lipoprotein cholesterol (HDL-C) (MD: 0.11, p < 0.01), whereas no significant effects were observed for cyanidin- and malvidin-based anthocyanins. Although non-significant, favorable effects on total cholesterol (TC) and HDL-C were observed for cyanidin- and malvidin-based anthocyanins, respectively (both p < 0.1). The ascending order of effectiveness on TC and LDL-C was delphinidin-, cyanidin-, and malvidin-based anthocyanins, and the differences among the three groups were significant (both p < 0.05). We could not confirm the significant effects of each main anthocyanin on glucose metabolism; however, insulin resistance index changed positively and negatively with cyanidin- and delphinidin-based anthocyanins, respectively. Therefore, foods containing mainly unmethylated anthocyanins, especially with large numbers of OH groups, may improve glucose and lipid metabolism more effectively than those containing methylated anthocyanins.

Download Full-text

Genetic variation of RNF145 gene and blood lipid levels in Xinjiang population, China

Scientific Reports ◽

10.1038/s41598-021-85503-z ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Jing Ming ◽

Xian Wei ◽

Min Han ◽

Dilare Adi ◽

Jialin Abuzhalihan ◽

...

Keyword(s):

Low Density Lipoprotein ◽

Ring Finger ◽

Density Lipoprotein ◽

Blood Lipid ◽

Lipid Profiles ◽

Cholesterol Levels ◽

General Linear Model Analysis ◽

Confounding Variables ◽

Before And After ◽

Detection Response

AbstractDyslipidemia is one of the main risk factors for coronary heart disease (CHD). The E3 ubiquitin ligase which is encoded by the ring finger protein 145 (RNF145) gene is very important in the mediation of cholesterol synthesis and effectively treats hypercholesterolemia. Thus, the purpose of the present research is to investigate the connection between the polymorphism of the RNF145 gene and cholesterol levels in the populations in Xinjiang, China. A total of 1396 participants (Male: 628, Female: 768) were included in this study for genetic analysis of RNF145 gene, and we used the modified multiple connection detection response (iMLDR) technology to label two SNPs (rs17056583, rs12188266) of RNF145 genotyping. The relationship between the genotypes and the lipid profiles was analyzed with general linear model analysis after adjusting confounding variables. Through the analysis of the two SNPs in RNF145 gene, we discovered that both rs17056583 and rs12188266 were related to total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations (All P < 0.001). In addition, the association of rs17056583 and rs12188266 with lipid profiles concentrations is still statistically significant after multivariate adjustment of sex, age, smoking, obesity, drinking, diabetes, hypertension and lipid profiles. Meanwhile, we also found that rs17056583 was associated with high triglycerides concentrations before and after adjustment (All P < 0.001). Our study shows that both rs17056583 and rs12188266 SNPs of RNP145 gene are related to TC and LDL-C concentrations in Xinjiang population.

Download Full-text

Daily Time Use by Activity of Community-Dwelling Older Koreans: Focus on Health Management

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18041688 ◽

2021 ◽

Vol 18 (4) ◽

pp. 1688

Author(s):

Hana Ko

Keyword(s):

Older Adults ◽

Time Use ◽

Health Management ◽

Subjective Evaluation ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Community Dwelling ◽

Senior Center ◽

The Mean ◽

Daily Time

This study aimed to examine the daily time use by activity and identified factors related to health management time (HMT) use among 195 older adults (mean age = 77.5, SD = 6.28 years; 70.8% women) attending a Korean senior center. Descriptive statistics were analyzed and gamma regression analyses were performed. Participants used the most time on rest, followed by leisure, health management, daily living activities, and work. The mean duration of HMT was 205.38 min/day. The mean score for the subjective evaluation of health management (SEHM) was 13.62 and the importance score for SEHM was 4.72. Factors influencing HMT included exercise, number of chronic conditions, fasting blood sugar level, low density lipoprotein level, and cognitive function. HMT and frailty significantly predicted SEHM. HMT interventions focus on promoting exercise and acquiring health information to improve health outcomes among older adults in senior centers.

Download Full-text